Analysis of HLA A*02 association with vaccine efficacy in the RV144 HIV-1 vaccine trial

Journal of Virology

Volumn 88, Issue 15, 2014, Pages 8242-8255

  Gartland, Andrew J ^a   Li, Sue ^a   McNevin, John ^a   Tomaras, Georgia D ^c   Gottardo, Raphael ^a   Janes, Holly ^a   Fong, Youyi ^a   Morris, Daryl ^a   Geraghty, Daniel E ^a   Kijak, Gustavo H ^d   Edlefsen, Paul T ^a   Frahm, Nicole ^a   Larsen, Brendan B ^e   Tovanabutra, Sodsai ^d   Sanders Buell, Eric ^f   deCamp, Allan C ^a   Magaret, Craig A ^a   Ahmed, Hasan ^a   Goodridge, Jodie P ^g   Chen, Lennie ^e   Konopa, Philip ^f   Nariya, Snehal ^f   Stoddard, Julia N ^f   Wong, Kim ^f   Zhao, Hong ^f   Deng, Wenjie ^f   Maust, Brandon S ^f   Bose, Meera ^d   Howell, Shana ^d   Bates, Adam ^d   Lazzaro, Michelle ^d   O'Sullivan, Annemarie ^d   Lei, Esther ^d   Bradfield, Andrea ^d   Ibitamuno, Grace ^d   Assawadarachai, Vatcharain ^h   O'Connell, Robert J ^d   deSouza, Mark S ^h   Nitayaphan, Sorachai ^h   Rerks Ngarm, Supachai ⁱ   Robb, Merlin L ^d   Sidney, John ^j   Sette, Alessandro ^j   Zolla Pazner, Susan ^k   Montefiori, David ^c   Juliana McElrath, M ^a   Mullins, James I ^e   Kim, Jerome H ^d   Gilbert, Peter B ^a   Hertz, Tomer ^a,b   more..

^a Fred Hutchinson Cancer Research Center   (United States)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d US Military HIV Research Program   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

^g OSLO UNIVERSITY HOSPITAL   (Norway)

^h ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

ⁱ MINISTRY OF PUBLIC HEALTH   (Thailand)

^j LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^k NEW YORK UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; GLYCOPROTEIN GP 120; HLA A 02 ANTIGEN; HLA A11 ANTIGEN; HLA ANTIGEN CLASS 1; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; LYSINE; PLACEBO; UNCLASSIFIED DRUG; GP120 PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; HLA A*02 ANTIGEN; HLA A2 ANTIGEN; HLA-A*02 ANTIGEN;

ALLELE; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; CELL SELECTION; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMORAL IMMUNITY; IMMUNE RESPONSE; INFECTION RISK; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; TREATMENT DURATION; VIRUS ENTRY; VIRUS GENOME; VIRUS LOAD; CLINICAL TRIAL; COHORT ANALYSIS; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; T LYMPHOCYTE;

AIDS VACCINES; COHORT STUDIES; GENETIC ASSOCIATION STUDIES; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HLA-A2 ANTIGEN; HUMANS; T-LYMPHOCYTES;

EID: 84903887355     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01164-14     Document Type: Article

References (84)

1. Plotkin S, Orenstein W, Offit P. 2008. Vaccines, 5th ed. Elsevier Inc., Philadelphia, PA.
2. Osterholm MT, Kelley NS, Sommer A, Belongia EA. 2012. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect. Dis. 12:36-44. http://dx.doi.org/10.1016/S1473-3099(11) 70295-X.
3. Fine PE. 1995. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 346:1339-1345. http://dx.doi.org/10.1016/S0140-6736(95)92348-9.
4. Poland GA, Kennedy RB, Ovsyannikova IG. 2011. Vaccinomics and personalized vaccinology: is science leading us toward a new path of directed vaccine development and discovery? PLoS Pathog. 7:e1002344. http://dx.doi.org/10.1371/journal.ppat.1002344.
5. Plotkin SA. 2010. Correlates of protection induced by vaccination. Clin. Vaccine Immunol. 17:1055-1065. http://dx.doi.org/10.1128/CVI.00131-10.
6. Haralambieva IH, Ovsyannikova IG, Kennedy RB, Larrabee BR, Shane Pankratz V, Poland GA. 2013. Race and sex-based differences in cytokine immune responses to smallpox vaccine in healthy individuals. Hum. Immunol. 74:1263-1266. http://dx.doi.org/10.1016/j.humimm.2013.06.031.
7. Haralambieva IH, Ovsyannikova IG, Umlauf BJ, Vierkant RA, Shane Pankratz V, Jacobson RM, Poland GA. 2011. Genetic polymorphisms in host antiviral genes: associations with humoral and cellular immunity to measles vaccine. Vaccine 29:8988-8997. http://dx.doi.org/10.1016/j.vaccine.2011.09.043.
8. Haralambieva IH, Oberg AL, Dhiman N, Ovsyannikova IG, Kennedy RB, Grill DE, Jacobson RM, Poland GA. 2012. High-dimensional gene expression profiling studies in high and low responders to primary smallpox vaccination. J. Infect. Dis. 206:1512-1520. http://dx.doi.org/10.1093/infdis/jis546.
9. Kennedy RB, Ovsyannikova IG, Pankratz VS, Haralambieva IH, Vierkant RA, Jacobson RM, Poland GA. 2012. Genome-wide genetic associations with IFNγ response to smallpox vaccine. Hum. Genet. 131:1433-1451. http://dx.doi.org/10.1007/s00439-012-1179-x.
10. Frahm N, DeCamp AC, Friedrich DP, Carter DK, Defawe OD, Kublin JG, Casimiro DR, Duerr A, Robertson MN, Buchbinder SP, Huang Y, Spies GA, De Rosa SC, McElrath MJ. 2012. Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine. J. Clin. Invest. 122:359-367. http://dx.doi.org/10.1172/JCI60202.
11. Zak DE, Andersen-Nissen E, Peterson ER, Sato A, Hamilton MK, Borgerding J, Krishnamurty AT, Chang JT, Adams DJ, Hensley TR, Salter AI, Morgan CA, Duerr AC, De Rosa SC, Aderem A, McElrath MJ. 14 November 2012. Merck Ad5/HIV induces broad innate immune activation that predicts CD8+ T-cell responses but is attenuated by preexisting Ad5 immunity. Proc. Natl. Acad. Sci. U.S.A. http://dx.doi.org/10.1073/pnas.1208972109.
12. McElrath MJ, De Rosa SC, Moodie Z, Dubey S, Kierstead L, Janes H, Defawe OD, Carter DK, Hural J, Akondy R, Buchbinder SP, Robertson MN, Mehrotra DV, Self SG, Corey L, Shiver JW, Casimiro DR. 2008. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 372:1894-1905. http://dx.doi.org/10.1016/S0140-6736(08)61592-5.
13. Montefiori DC, Metch B, McElrath MJ, Self S, Weinhold KJ, Corey L. 2004. Demographic factors that influence the neutralizing antibody response in recipients of recombinant HIV-1 gp120 vaccines. J. Infect. Dis. 190:1962-1969. http://dx.doi.org/10.1086/425518.
14. Rerks-Ngarm S, Pitisuttithum P. 2009. Vaccination with ALVAC and ADISVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361: 2209-2220. http://dx.doi.org/10.1056/NEJMoa0908492.
15. Haynes BF, Gilbert PB, McElrath M, Zolla-Pazner S, Tomaras GD, Alam SM, Evans DT, Montefiori DC, Karnasuta C, Sutthent R, Liao H-X, DeVico AL, Lewis GK, Williams C, Pinter A, Fong Y, Janes H, DeCamp A, Huang Y, Rao M, Billings E, Karasavvas N, Robb ML, Ngauy V, de Souza MS, Paris R, Ferrari G, Bailer RT, Soderberg KA, Andrews C, Berman PW, Frahm N, De Rosa SC, Alpert MD, Yates NL, Shen X, Koup RA, Pitisuttithum P, Kaewkungwal J, Nitayaphan S, Rerks-Ngarm S, Michael NL, Kim JH, Alam M. 2012. Immunecorrelates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 366:1275-1286. http://dx.doi.org/10.1056/NEJMoa1113425.
16. Zolla-Pazner S, Decamp AC, Cardozo T, Karasavvas N, Gottardo R, Williams C, Morris DE, Tomaras G, Rao M, Billings E, Berman P, Shen X, Andrews C, O'Connell RJ, Ngauy V, Nitayaphan S, de Souza M, Korber B, Koup R, Bailer RT, Mascola JR, Pinter A, Montefiori D, Haynes BF, Robb ML, Rerks-Ngarm S, Michael NL, Gilbert PB, Kim JH. 2013. Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 Vaccine Efficacy Trial. PLoS One 8:e53629. http://dx.doi.org/10.1371/journal.pone.0053629.
17. Rolland M, Edlefsen PT, Larsen BB, Tovanabutra S, Sanders-Buell E, Hertz T, deCamp AC, Carrico C, Menis S, Magaret CA, Ahmed H, Juraska M, Chen L, Konopa P, Nariya S, Stoddard JN, Wong K, Zhao H, Deng W, Maust BS, Bose M, Howell S, Bates A, Lazzaro M, O'Sullivan A, Lei E, Bradfield A, Ibitamuno G, Assawadarachai V, O'Connell RJ, deSouza MS, Nitayaphan S, Rerks-Ngarm S, Robb ML, McLellan JS, Georgiev I, Kwong PD, Carlson JM, Michael NL, Schief WR, Gilbert PB, Mullins JI, Kim JH. 10 September 2012. Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature http://dx.doi.org/10.1038/nature11519.
18. Karasavvas N, Billings E, Rao M, Williams C, Zolla-Pazner S, Bailer RT, Koup RA, Madnote S, Arworn D, Shen X, Tomaras GD, Currier JR, Jiang M, Magaret C, Andrews C, Gottardo R, Gilbert P, Cardozo TJ, Rerks-Ngarm S, Nitayaphan S, Pitisuttithum P, Kaewkungwal J, Paris R, Greene K, Gao H, Gurunathan S, Tartaglia J, Sinangil F, Korber BT, Montefiori DC, Mascola JR, Robb ML, Haynes BF, Ngauy V, Michael NL, Kim JH, de Souza MS; MOPH TAVEG Collaboration. 2012. The Thai Phase III HIV Type 1 Vaccine Trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120. AIDS Res. Hum. Retroviruses 28:1444-1457. http://dx.doi.org/10.1089/aid.2012.0103.
19. de Souza MS, Ratto-Kim S, Chuenarom W, Schuetz A, Chantakulkij S, Nuntapinit B, Valencia-Micolta A, Thelian D, Nitayaphan S, Pitisuttithum P, Paris RM, Kaewkungwal J, Michael NL, Rerks-Ngarm S, Mathieson B, Marovich M, Currier JR, Kim JH. 2012. The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope. J. Immunol. 188: 5166-5176. http://dx.doi.org/10.4049/jimmunol.1102756.
20. Montefiori DDC, Karnasuta C, Huang Y, Ahmed H, Gilbert P, de Souza MS, McLinden R, Tovanabutra S, Laurence-Chenine A, Sanders-Buell E, Moody MA, Bonsignori M, Ochsenbauer C, Kappes J, Tang H, Greene K, Gao H, LaBranche CC, Andrews C, Polonis VR, Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Self SG, Berman PW, Francis D, Sinangil F, Lee C, Tartaglia J, Robb ML, Haynes BF, Michael NL, Kim JH. 2012. Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J. Infect. Dis. 206:431-441. http://dx.doi.org/10.1093/infdis/jis367.
21. Liu P, Yates NL, Shen X, Bonsignori M, Moody MA, Liao H-X, Fong Y, Alam SM, Overman RG, Denny T, Ferrari G, Ochsenbauer C, Kappes JC, Polonis V, Pitisuttithum P, Kaewkungwal J, Nitayaphan S, Rerks-Ngarm S, Montefiori DC, Gilbert P, Michael NL, Kim JH, Haynes BF, Tomaras GD. 8 May 2013. Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccinees. J. Virol. http://dx.doi.org/10.1128/JVI.02737-12.
22. Liao H-X, Bonsignori M, Alam SM, McLellan JS, Tomaras GD, Moody MA, Kozink DM, Hwang K-K, Chen X, Tsao C-Y, Liu P, Lu X, Parks RJ, Montefiori DC, Ferrari G, Pollara J, Rao M, Peachman KK, Santra S, Letvin NL, Karasavvas N, Yang Z-Y, Dai K, Pancera M, Gorman J, Wiehe K, Nicely NI, Rerks-Ngarm S, Nitayaphan S, Kaewkungwal J, Pitisuttithum P, Tartaglia J, Sinangil F, Kim JH, Michael NL, Kepler TB, Kwong PD, Mascola JR, Nabel GJ, Pinter A, Zolla-Pazner S, Haynes BF. 11 January 2013. Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity http://dx.doi.org/10.1016/j.immuni.2012.11.011.
23. Zolla-Pazner S, Decamp A, Gilbert PB, Williams C, Yates NL, Williams WT, Howington R, Fong Y, Morris DE, Soderberg KA, Irene C, Reichman C, Pinter A, Parks R, Pitisuttithum P, Kaewkungwal J, Rerks-Ngarm S, Nitayaphan S, Andrews C, O'Connell RJ, Yang Z-Y, Nabel GJ, Kim JH, Michael NL, Montefiori DC, Liao H-X, Haynes BF, Tomaras GD. 2014. Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection. PLoS One 9:e87572. http://dx.doi.org/10.1371/journal.pone.0087572.
24. Yates NL, Liao H-X, Fong Y, deCamp A, Vandergrift NA, Williams WT, Alam SM, Ferrari G, Yang Z-Y, Seaton KE, Berman PW, Alpert MD, Evans DT, O'Connell RJ, Francis D, Sinangil F, Lee C, Nitayaphan S, Rerks-Ngarm S, Kaewkungwal J, Pitisuttithum P, Tartaglia J, Pinter A, Zolla-Pazner S, Gilbert PB, Nabel GJ, Michael NL, Kim JH, Montefiori DC, Haynes BF, Tomaras GD. 2014. Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination. Sci. Transl. Med. 6:228ra39. http://dx.doi.org/10.1126/scitranslmed.3007730.
25. Rolland M, Tovanabutra S, DeCamp AC, Frahm N, Gilbert PB, Sanders-Buell E, Heath L, Magaret CA, Bose M, Bradfield A, O'Sullivan A, Crossler J, Jones T, Nau M, Wong K, Zhao H, Raugi DN, Sorensen S, Stoddard JN, Maust BS, Deng W, Hural J, Dubey S, Michael NL, Shiver J, Corey L, Li F, Self SG, Kim J, Buchbinder S, Casimiro DR, Robertson MN, Duerr A, McElrath MJ, McCutchan FE, Mullins JI. 2011. Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial. Nat. Med. 17:366-371. http://dx.doi.org/10.1038/nm.2316.
26. Sun Y, Gilbert PB. 2012. Estimation of stratified mark-specific proportional hazards models with missing marks. Scand. Stat. Theory Appl. 39: 34-52. http://dx.doi.org/10.1111/j.1467-9469.2011.00746.x.
27. Henn MR, Boutwell CL, Charlebois P, Lennon NJ, Power KA, Macalalad AR, Berlin AM, Malboeuf CM, Ryan EM, Gnerre S, Zody MC, Erlich RL, Green LM, Berical A, Wang Y, Casali M, Streeck H, Bloom AK, Dudek T, Tully D, Newman R, Axten KL, Gladden AD, Battis L, Kemper M, Zeng Q, Shea TP, Gujja S, Zedlack C, Gasser O, Brander C, Hess C, Günthard HF, Brumme ZL, Brumme CJ, Bazner S, Rychert J, Tinsley JP, Mayer KH, Rosenberg E, Pereyra F, Levin JZ, Young SK, Jessen H, Altfeld M, Birren BW, Walker BD, Allen TM. 2012. Whole genome deep sequencing of HIV-1 reveals the impact of early minor variants upon immune recognition during acute infection. PLoS Pathog. 8:e1002529. http://dx.doi.org/10.1371/journal.ppat.1002529.
28. Goonetilleke N, Liu MKP, Salazar-Gonzalez JF, Ferrari G, Giorgi E, Ganusov VV, Keele BF, Learn GH, Turnbull EL, Salazar MG, Weinhold KJ, Moore S, Letvin N, Haynes BF, Cohen MS, Hraber P, Bhattacharya T, Borrow P, Perelson AS, Hahn BH, Shaw GM, Korber BT, McMichael AJ. 2009. The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J. Exp. Med. 206: 1253-1272. http://dx.doi.org/10.1084/jem.20090365.
29. Ferrari G, Korber B, Goonetilleke N, Liu MKP, Turnbull EL, Salazar-Gonzalez JF, Hawkins N, Self S, Watson S, Betts MR, Gay C, McGhee K, Pellegrino P, Williams I, Tomaras GD, Haynes BF, Gray CM, Borrow P, Roederer M, McMichael AJ, Weinhold KJ. 2011. Relationship between functional profile of HIV-1 specific CD8 T cells and epitope variability with the selection of escape mutants in acute HIV-1 infection. PLoS Pathog. 7:e1001273. http://dx.doi.org/10.1371/journal.ppat.1001273.
30. Soghoian DZ, Jessen H, Flanders M, Sierra-Davidson K, Cutler S, Pertel T, Ranasinghe S, Lindqvist M, Davis I, Lane K, Rychert J, Rosenberg ES, Piechocka-Trocha A, Brass AL, Brenchley JM, Walker BD, Streeck H. 2012. HIV-specific cytolytic CD4 T cell responses during acute HIV infection predict disease outcome. Sci. Transl. Med. 4:123ra25. http://dx.doi.org/10.1126/scitranslmed.3003165.
31. Herbeck JT, Rolland M, Liu Y, McLaughlin S, McNevin J, Zhao H, Wong K, Stoddard JN, Raugi D, Sorensen S, Genowati I, Birditt B, McKay A, Diem K, Maust BS, Deng W, Collier AC, Stekler JD, Mc-Elrath MJ, Mullins JI. 2011. Demographic processes affect HIV-1 evolution in primary infection before the onset of selective processes. J. Virol. 85:7523-7534. http://dx.doi.org/10.1128/JVI.02697-10.
32. Nitayaphan S, Pitisuttithum P, Karnasuta C, Eamsila C, de Souza M, Morgan P, Polonis V, Benenson M, VanCott T, Ratto-Kim S, Kim J, Thapinta D, Garner R, Bussaratid V, Singharaj P, El-Habib R, Gurunathan S, Heyward W, Birx D, McNeil J, Brown AE. 2004. Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults. J. Infect. Dis. 190:702-706. http://dx.doi.org/10.1086/422258.
33. Jojic N, Reyes-Gomez M, Heckerman D, Kadie C, Schueler-Furman O. 2006. Learning MHC I-peptide binding. Bioinformatics 22:e227-e235. http://dx.doi.org/10.1093/bioinformatics/btl255.
34. Nielsen M, Lundegaard C, Blicher T, Lamberth K, Harndahl M, Justesen S, Røder G, Peters B, Sette A, Lund O, Buus S. 2007. NetMHCpan, a method for quantitative predictions of peptide binding to any HIV-1-A and-B locus protein of known sequence. PLoS One 2:e796. http://dx.doi.org/10.1371/journal.pone.0000796.
35. Nielsen M, Justesen S, Lund O, Lundegaard C, Buus S. 2010. Net-MHCIIpan-2.0-improved pan-specific HLA-DR predictions using a novel concurrent alignment and weight optimization training procedure. Immunome Res. 6:9. http://dx.doi.org/10.1186/1745-7580-6-9.
36. Poland GA, Ovsyannikova I, Jacobson R. 12 September 2008. Immunogenetics of seasonal influenza vaccine response. Vaccine http://dx.doi.org/10.1016/j.vaccine.2008.07.065.
37. Alper CA, Kruskall MS, Marcus-Bagley D, Craven DE, Katz AJ, Brink SJ, Dienstag JL, Awdeh Z, Yunis EJ. 1989. Genetic prediction of nonresponse to hepatitis B vaccine. N. Engl. J. Med. 321:708-712. http://dx.doi.org/10.1056/NEJM198909143211103.
38. Ovsyannikova IG, Jacobson RM, Poland GA. 2004. Variation in vaccine response in normal populations. Pharmacogenomics 5:417-427. http://dx.doi.org/10.1517/14622416.5.4.417.
39. Ovsyannikova IG, Pankratz VS, Vierkant RA, Jacobson RM, Poland GA. 2012. Consistency of HLA associations between two independent measles vaccine cohorts: a replication study. Vaccine 30:2146-2152. http://dx.doi.org/10.1016/j.vaccine.2012.01.038.
40. Ovsyannikova IG, Jacobson RM, Vierkant RA, O'Byrne MM, Poland GA. 2009. Replication of rubella vaccine population genetic studies: validation of HLA genotype and humoral response associations. Vaccine 27: 6926-6931. http://dx.doi.org/10.1016/j.vaccine.2009.08.109.
41. Edlefsen PT, Gilbert PB, Rolland M. 2013. Sieve analysis in HIV-1 vaccine efficacy trials. Curr. Opin. HIV AIDS 8:432-436. http://dx.doi.org/10.1097/COH.0b013e328362db2b.
42. Schueler-Furman O, Altuvia Y, Sette A, Margalit H. 2000. Structurebased prediction of binding peptides to MHC class I molecules: application to a broad range of MHC alleles. Protein Sci. 9:1838-1846. http://dx.doi.org/10.1110/ps.9.9.1838.
43. Hurley CK, Mack SJ, Mickelson E, Marsh S, Tilanus MGJ, Gorodezky C, Wade JA, Müller C, Hartzman RJ, Baxter-Lowe LA, Raffoux C. 2006. HLA typing and informatics, in immunobiology of the human MHC, p 179-352. In J. A. Hansen (ed), 13th International Histocompatibility Workshop protocols. IHWG Press, Seattle, WA.
44. Lancaster AK, Single RM, Solberg OD, Nelson MP, Thomson G. 2007. PyPop update-a software pipeline for large-scale multilocus population genomics. Tissue Antigens 69(Suppl 1):S192-S197. http://dx.doi.org/10.1111/j.1399-0039.2006.00769.x.
45. Dai JY, Li SS, Gilbert PB. 27 June 2013. Case-only method for causespecific hazards models with application to assessing differential vaccine efficacy by viral and host genetics. Biostatistics http://dx.doi.org/10.1093/biostatistics/kxt018.
46. Zelen M. 1971. The analysis of several 2 × 2 contingency tables. Biometrika 58:129-137. http://dx.doi.org/10.1093/biomet/58.1.129.
47. Pereyra F, Jia X, McLaren PJ, Telenti A, de Bakker PIW, Walker BD, Ripke S, Brumme CJ, Pulit SL, Carrington M, Kadie CM, Carlson JM, Heckerman D, Graham RR, Plenge RM, Deeks SG, Gianniny L, Crawford G, Sullivan J, Gonzalez E, Davies L, Camargo A, Moore JM, Beattie N, Gupta S, Crenshaw A, Burtt NP, Guiducci C, Gupta N, Gao X, Qi Y, Yuki Y, Piechocka-Trocha A, Cutrell E, Rosenberg R, Moss KL, Lemay P, O'Leary J, Schaefer T, Verma P, Toth I, Block B, Baker B, Rothchild A, Lian J, Proudfoot J, Alvino DML, Vine S, Addo MM, et al. 2010. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science 330:1551-1557. http://dx.doi.org/10.1126/science.1195271.
48. Sidney J, Southwood S, Oseroff C, del Guercio MF, Sette A, Grey HM. 2001. Measurement of MHC/peptide interactions by gel filtration. Curr. Protoc. Immunol. 31:18.3.1-18.3.19. http://dx.doi.org/10.1002/0471142735.im1803s31.
49. Sidney J, Assarsson E, Moore C, Ngo S, Pinilla C, Sette A, Peters B. 2008. Quantitative peptide binding motifs for 19 human and mouseMHC class I molecules derived using positional scanning combinatorial peptide libraries. Immunome Res. 4:2. http://dx.doi.org/10.1186/1745-7580-4-2.
50. Sidney J, Southwood S, Mann DL, Fernandez-Vina MA, Newman MJ, Sette A. 2001. Majority of peptides binding HIV-1 A*0201 with high affinity crossreact with other A2-supertype molecules. Hum. Immunol. 62:1200-1216. http://dx.doi.org/10.1016/S0198-8859(01)00319-6.
51. Cheng Y, Prusoff WH. 1973. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 22:3099-3108. http://dx.doi.org/10.1016/0006-2952(73)90196-2.
52. Gulukota K, Sidney J, Sette A, DeLisi C. 1997. Two complementary methods for predicting peptides binding major histocompatibility complex molecules. J. Mol. Biol. 267:1258-1267. http://dx.doi.org/10.1006/jmbi.1997.0937.
53. Tomaras GD, Ferrari G, Shen X, Alam SM, Liao H-X, Pollara J, Bonsignori M, Moody MA, Fong Y, Chen X, Poling B, Nicholson CO, Zhang R, Lu X, Parks R, Kaewkungwal J, Nitayaphan S, Pitisuttithum P, Rerks-Ngarm S, Gilbert PB, Kim JH, Michael NL, Montefiori DC, Haynes BF. 9 May 2013. Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG. Proc. Natl. Acad. Sci. U.S.A. http://dx.doi.org/10.1073/pnas.1301456110.
54. Crotty S. 2011. Follicular helper CD4 T cells (TFH). Annu. Rev. Immunol. 29:621-663. http://dx.doi.org/10.1146/annurev-immunol-031210-101400.
55. + T cell epitope hotspots to exposed strands of HIV envelope glycoprotein suggests structural influences on antigen processing. Proc. Natl. Acad. Sci. U.S.A. 98:4587-4592. http://dx.doi.org/10.1073/pnas.071063898.
56. + and CD8+ T cell subpopulations. AIDS Res. Hum. Retroviruses 23:471-476. http://dx.doi.org/10.1089/aid.2006.0241.
57. Yu B, Fonseca DPA, O'Rourke JSM, Berman PW. 2010. Protease cleavage sites in HIV-1 gp120 recognized by antigen processing enzymes are conserved and located at receptor binding sites. J. Virol. 84:1513-1526. http://dx.doi.org/10.1128/JVI.01765-09.
58. Steers NJ, Ratto-Kim S, de Souza MS, Currier JR, Kim JH, Michael NL, Alving CR, Rao M. 2012. HIV-1 envelope resistance to proteasomal cleavage: implications for vaccine induced immune responses. PLoS One 7:e42579. http://dx.doi.org/10.1371/journal.pone.0042579.
59. Janes H, Frahm N, DeCamp A, Rolland M, Gabriel E, Wolfson J, Hertz T, Kallas E, Goepfert P, Friedrich DP, Corey L, Mullins JI, McElrath MJ, Gilbert P. 2012. MRKAd5 HIV-1 Gag/Pol/Nef vaccine-induced Tcell responses inadequately predict distance of breakthrough HIV-1 sequences to the vaccine or viral load. PLoS One 7:e43396. http://dx.doi.org/10.1371/journal.pone.0043396.
60. Mudd PA, Martins MA, Ericsen AJ, Tully DC, Power KA, Bean AT, Piaskowski SM, Duan L, Seese A, Gladden AD, Weisgrau KL, Furlott JR, Kim YI, Veloso de Santana MG, Rakasz E, Capuano S, III, Wilson NA, Bonaldo MC, Galler R, Allison DB, Piatak M, Jr, Haase AT, Lifson JD, Allen TM, Watkins DI. 30 September 2012. Vaccine-induced CD8(+) T cells control AIDS virus replication. Nature http://dx.doi.org/10.1038/nature11443.
61. Fukazawa Y, Park H, Cameron MJ, Lefebvre F, Lum R, Coombes N, Mahyari E, Hagen SI, Bae JY, Reyes MD, III, Swanson T, Legasse AW, Sylwester A, Hansen SG, Smith AT, Stafova P, Shoemaker R, Li Y, Oswald K, Axthelm MK, McDermott A, Ferrari G, Montefiori DC, Edlefsen PT, Piatak M, Jr, Lifson JD, Sékaly RP, Picker LJ. 9 September 2012. Lymph node T cell responses predict the efficacy of live attenuated SIV vaccines. Nat. Med. http://dx.doi.org/10.1038/nm.2934.
62. Hansen SG, Ford JC, Lewis MS, Ventura AB, Hughes CM, Coyne-Johnson L, Whizin N, Oswald K, Shoemaker R, Swanson T, Legasse AW, Chiuchiolo MJ, Parks CL, Axthelm MK, Nelson JA, Jarvis MA, Piatak M, Jr, Lifson JD, Picker LJ. 2011. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 473:523-527. http://dx.doi.org/10.1038/nature10003.
63. Hansen SG, Piatak M, Jr, Ventura AB, Hughes CM, Gilbride RM, Ford JC, Oswald K, Shoemaker R, Li Y, Lewis MS, Gilliam AN, Xu G, Whizin N, Burwitz BJ, Planer SL, Turner JM, Legasse AW, Axthelm MK, Nelson JA, Früh K, Sacha JB, Estes JD, Keele BF, Edlefsen PT, Lifson JD, Picker LJ. 11 September 2013. Immune clearance of highly pathogenic SIV infection. Nature http://dx.doi.org/10.1038/nature12519.
64. Fuller DH, Rajakumar P, Che JW, Narendran A, Nyaundi J, Michael H, Yager EJ, Stagnar C, Wahlberg B, Taber R, Haynes JR, Cook FC, Ertl P, Tite J, Amedee AM, Murphey-Corb M. 2012. Therapeutic DNA vaccine induces broad T cell responses in the gut and sustained protection from viral rebound and AIDS in SIV-infected rhesus macaques. PLoS One 7:e33715. http://dx.doi.org/10.1371/journal.pone.0033715.
65. + T-cell epitopes. J. Virol. 81:3667-3672. http://dx.doi.org/10.1128/JVI.02689-06.
66. Duda A, Lee-Turner L, Fox J, Robinson N, Dustan S, Kaye S, Fryer H, Carrington M, McClure M, McLean A, Fidler RS, Weber J, Phillips RE, Frater AJ. 2009. HIV-1-infected ssociated clinical progression correlates with epitope reversion rates in early human immunodeficiency virus infection. J. Virol. 83:1228-1239. http://dx.doi.org/10.1128/JVI.01545-08.
67. Chen H, Ndhlovu ZM, Liu D, Porter LC, Fang JW, Darko S, Brockman MA, Miura T, Brumme ZL, Schneidewind A, Piechocka-Trocha A, Cesa KT, Sela J, Cung TD, Toth I, Pereyra F, Yu XG, Douek DC, Kaufmann DE, Allen TM, Walker BD. 10 June 2012. TCR clonotypes modulate the protective effect of HLA class I molecules in HIV-1 infection. Nat. Immunol. http://dx.doi.org/10.1038/ni.2342.
68. Shea PR, Shianna KV, Carrington M, Goldstein DB. 27 September 2012. Host genetics of HIV acquisition and viral control. Annu. Rev. Med. http://dx.doi.org/10.1146/annurev-med-052511-135400.
69. Song H, Pavlicek JW, Cai F, Bhattacharya T, Li H, Iyer SS, Bar KJ, Decker JM, Goonetilleke N, Liu MKP, Berg A, Hora B, Drinker MS, Eudailey J, Pickeral J, Moody MA, Ferrari G, McMichael A, Perelson AS, Shaw GM, Hahn BH, Haynes BF, Gao F. 2012. Impact of immune escape mutations on HIV-1 fitness in the context of the cognate transmitted/founder genome. Retrovirology 9:89. http://dx.doi.org/10.1186/1742-4690-9-89.
70. Carrington M, Nelson GW, Martin MP, Kissner T, Vlahov D, Goedert JJ, Kaslow R, Buchbinder S, Hoots K, O'Brien SJ. 1999. HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage. Science 283: 1748-1752. http://dx.doi.org/10.1126/science.283.5408.1748.
71. Kaslow RA, Carrington M, Apple R, Park L, Muñoz A, Saah AJ, Goedert JJ, Winkler C, O'Brien SJ, Rinaldo C, Detels R, Blattner W, Phair J, Erlich H, Mann DL. 1996. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat. Med. 2:405-411. http://dx.doi.org/10.1038/nm0496-405.
72. + T-cell responses to different HIV proteins have discordant associations with viral load. Nat. Med. 13:46-53. http://dx.doi.org/10.1038/nm1520.
73. Chaturvedi U, Nagar R, Shrivastava R. 2006. Dengue and dengue haemorrhagic fever: implications of host genetics. FEMS Immunol. Med. Microbiol. 47:155-166. http://dx.doi.org/10.1111/j.1574-695X.2006.00058.x.
74. Macnamara A, Rowan A, Hilburn S, Kadolsky U, Fujiwara H, Suemori K, Yasukawa M, Taylor G, Bangham CRM, Asquith B. 2010. HLA class I binding of HBZ determines outcome in HTLV-1 infection. PLoS Pathog. 6:e1001117. http://dx.doi.org/10.1371/journal.ppat.1001117.
75. Ovsyannikova IG, Jacobson RM, Vierkant RA, Jacobsen SJ, Pankratz VS, Poland GA. 2004. The contribution of HLA class I antigens in im-mune status following two doses of rubella vaccination. Hum. Immunol. 65:1506-1515. http://dx.doi.org/10.1016/j.humimm.2004.07.001.
76. Goodridge JP, Lee N, Burian A, Pyo C-W, Tykodi SS, Warren EH, Yee C, Riddell SR, Geraghty DE. 2013. HLA-F and MHC-I open conformers cooperate in a MHC-I antigen cross-presentation pathway. J. Immunol. 191:1567-1577. http://dx.doi.org/10.4049/jimmunol.1300080.
77. Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF. 2005. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J. Infect. Dis. 191:654-665. http://dx.doi.org/10.1086/428404.
78. Russell ND, Graham BS, Keefer MC, McElrath MJ, Self SG, Weinhold KJ, Montefiori DC, Ferrari G, Horton H, Tomaras GD, Gurunathan S, Baglyos L, Frey SE, Mulligan MJ, Harro CD, Buchbinder SP, Baden LR, Blattner WA, Koblin BA, Corey L; National Institute of Allergy and Infectious Diseases HIV Vaccine Trials Network. 2007. Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial. J. Acquir. Immune Defic. Syndr. 44:203-212. http://dx.doi.org/10.1097/01.qai.0000248356.48501.ff.
79. Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M, van Griensven F, Hu D, Tappero JW, Choopanya K; Bangkok Vaccine Evaluation Group. 3 November 2006. Efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. Vaccine http://dx.doi.org/10.1086/508748.
80. Chen AT, Cornberg M, Gras S, Guillonneau C, Rossjohn J, Trees A, Emonet S, de la Torre JC, Welsh RM, Selin LK. 2012. Loss of anti-viral immunity by infection with a virus encoding a cross-reactive pathogenic epitope. PLoS Pathog. 8:e1002633. http://dx.doi.org/10.1371/journal.ppat.1002633.
81. + T cells contribute to lymphoproliferation in Epstein-Barr virus-associated infectious mononucleosis. J. Clin. Invest. http://dx.doi.org/10.1172/JCI25078.
82. Zolla-Pazner S, Cardozo T. 2010. Structure-function relationships of HIV-1 envelope sequence-variable regions refocus vaccine design. Nat. Rev. Immunol. 10:527-535. http://dx.doi.org/10.1038/nri2801.
83. Romphruk AV, Kongmaroeng C, Klumkrathok K, Paupairoj C, Leelayuwat C. 2010. HLA class I and II alleles and haplotypes in ethnic Northeast Thais. Tissue Antigens 75:701-711. http://dx.doi.org/10.1111/j.1399-0039.2010.01448.x.
84. Schuetz A, Huangngern Y, de Souza M, Sukhumvittaya S, Jongrakthaitae S, Rerknimitr R, Saengtawan P, Ananworanich J, Vasan S, Ratto-Kim S, Pitisuttithum P, Michael N, O'Connell R, Ngauy V, Rerks-Ngarm S, Kim J. 2013. Evaluation of peripheral and mucosal cellular immune responses induced by late boost strategies in HIV-negative participants prior enrolled in RV144. AIDS Vaccine 2013, P12.56 LB. http://epostersonline.com/aidsvax2013/?q=node/4295.